logo-loader
viewMarks and Spencer Group PLC

Marks & Spencer to cut 525 jobs in shake-up

Retail giant to overhaul head office and IT staffing

Marks & Spencer shop sign
M&S employs over 3,500 people across its seven UK head offices

Troubled retail giant Marks & Spencer Group Plc (LON:MKS) is cutting about 525 head office jobs as part of a shake-up.

M&S said the jobs would go through redundancies, employing fewer contractors and not replacing staff who leave.

It is part of new chief executive Steve Rowe's efforts to turn around the group, which has struggled to revive its flagging clothing business.

The group said the cuts would not affect store staff, but would reduce permanent roles in cenral London by about 400, across IT and logistics.

It is consulting staff reps on the plans, which should save the chain 1% of total UK costs, although costs this year are still expected to rise by 3.5%.

There would be a non-underlying cost of about £15mln including changes to senior management that have already taken place.

Rowe said the group's business review had highlighted that it had become too complex and inefficient.

“M&S has to become a simpler and more effective organisation if we are to achieve our plans to recover and grow our business," he said.

The proposed reduction in roles would comprise existing vacancies, about 260 M&S roles and 200 contractors.

M&S employs over 3,500 people across its seven UK head offices.

Quick facts: Marks and Spencer Group PLC

Price: 179.45 GBX

LSE:MKS
Market: LSE
Market Cap: £3.5 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Polarean Imaging achieves positive phase III results in two...

Polarean Imaging PLC (LON:POLX) CEO Richard Hullihen tells Proactive its two phase III clinical trials have 'demonstrated handily' that its technology allows doctors and surgeons to visualize aspects of lung function that have gone undetected using traditional magnetic resonances imaging (MRI)...

57 minutes ago

RNS

Director/PDMR Shareholding

1 day, 10 hours ago

Director/PDMR Shareholding

2 weeks, 1 day ago

3rd Quarter Trading Statement

2 weeks, 6 days ago

Interim Chief Financial Officer

3 weeks, 5 days ago

Total Voting Rights

3 weeks, 6 days ago

Block listing Interim Review

3 weeks, 6 days ago

Director/PDMR Shareholding

4 weeks, 2 days ago

Holding(s) in Company

on 23/12/19

2 min read